View Exam | PowerPak

1. After 10 years, the risk of colorectal cancer for any individual with ulcerative colitis (UC) is estimated to be at what percentage?

A. 5% B. 2% C. 10% D. 15%

2. According to the Montreal Classification System (MCS), left-sided UC (distal colitis)

A. Is limited to the rectum B. Extends proximal to the splenic flexure C. Is limited to the colorectum distal to the splenic flexure D. None of the above

3. Which of the following statements is correct regarding 5-ASA enemas used in the treatment of patients with UC:

A. 1 g and 4 g doses of 5-amino-salacylic acid (5-ASA) enema therapy have shown similar efficacy in dose-response clinical trials B. 5-ASA enema PLUS oral 5-ASA therapy is more effective than monotherapy in patients with refractory distal UC C. Enema formulations have shown the ability to reach as far as the splenic flexure D. All of the above

4. According to a systematic review of clinical trials comparing oral sulfasalazine with oral 5-ASA compounds, which of the following correctly represents the number of patients who reported at least 1 adverse event:

A. Fourfold higher in patients who were treated with sulfasalazine B. Fourfold higher in patients who were treated with 5-ASA C. Twofold higher in patients who were treated with sulfasalazine D. Twofold higher in patients who were treated with 5-ASA

5. According to a pooled analysis of the Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND) studies, the most efficacious 5-ASA daily dose in patients with moderate UC severity is which of the following:

A. 2.4 g B. 1.6 g C. 4.8 g D. 3.3 g

6. Which of the following statements is correct regarding the use of corticosteroids in the treatment of UC:

A. Topical corticosteroids are not recommended for the maintenance of remission in patients with distal UC B. Corticosteroids are recommended to be tapered by 5 to 10 mg per week until 20 mg is reached, followed by gradual reductions of 2.5 mg per week C. Corticosteroid daily doses higher than 60 mg of intravenous (IV) methylprednisolone have shown limited benefit in patients hospitalized with severe UC D. All of the above

7. All of the following statements are correct regarding the use of azathioprine for the treatment of UC, EXCEPT:

A. Routine monitoring of 6-thioguanine nucleotides (6-TGN) levels is strongly recommended in clinical practice B. Patients have shown a threefold increased risk of acquiring opportunistic infections C. Thiopurine methyltransferase (TPMT) assays are recommended by the FDA before commencing treatment D. The onset of action of azathioprine is approximately 3 to 6 months

8. Which of the following statements is NOT correct with regard to infliximab:

A. 10 mg/kg doses were statistically superior to 5 mg/kg doses in the Active Ulcerative Colitis Trial (ACT) 1 and ACT 2 trials with regard to clinical response rates B. Infliximab is contraindicated in active infection C. Infliximab is usually reserved for patients who are refractory to steroids or who are steroid dependent D. All of the above

9. According to American College of Gastroenterology (ACG) guidelines, patients treated with triple immunosuppressant therapy (i.e., calcineurin inhibitor, corticosteroid, thiopurine) should be given antimicrobial prophylaxis to cover which of the following organisms:

A. Pneumocystis jirovecii B. Clostridium difficile C. Escherichia coli D. Treponema pallidum